

HTA Agencies' Expectations for Caregiver Quality of Life Considerations in CEA: A Focus on Pediatric Indications




Lisa SUTOUR^a, Noémie ALLALI^b, Anne-Lise VATAIRE^b
^aSanofi, Cambridge, USA ; ^bSanofi, Gentilly, France

INTRODUCTION

- A caregiver is a patient's close relative – such as a parent – who willingly provides needed assistance. Being a caregiver entails time, financial and emotional burdens. Numerous studies have shown a decline in Health- Related Quality of Life (HRQoL) for caregivers, especially when the patient is a child.
- Given the focus on pediatric diseases, there is a clear rationale to support the inclusion of caregiver HRQoL in Health Technology Assessments (HTA).
- However, HTA agencies have differing opinions on this inclusion in their Cost Effectiveness Analyses (CEAs): some are in favor, some are against, and some remain unclear. NICE seems to discuss and considers the most caregivers' QoL.¹
- Despite these discussions, there is a lack of methodological guidance to consider caregiver HRQoL into CEAs.
- This study highlights the methodological expectations of HTA agencies with the objective of providing guidance for potential future submission, based on pediatric case studies.

METHODS

- A systematic review of NICE appraisals for pediatric indications that included caregiver utility in their CEA between January 2019 and May 2023 was performed.
- European (HAS, ZiN, TLV), American (CADTH, ICER) and Australia (PBAC) HTA appraisals for the same indication were then identified and analyzed.
- The data collected from these assessments were intended to answer the following questions :



RESULTS

IDENTIFICATION OF NICE AND OTHER HTA APPRAISALS FOR PEDIATRIC INDICATIONS THAT CONSIDERED CAREGIVER HRQOL

- Between January 2019 and May 2023, caregiver consideration was found in **16 of 36 NICE appraisals for pediatric indications**.
- Of the 16 indications assessed by NICE, **7** have also been assessed by at least one HTA agency with caregiver utility data considered or discussed. The 7 indications identified are detailed in **Table 1**.

COMPARISON BETWEEN NICE AND OTHER HTA APPRAISALS

- A comparison of the **assumption regarding caregiver consideration** in the CEA between NICE and other HTAs is materialized thanks to a color coding in **Table 1**.
- While NICE's assessment considered caregivers, other agencies do not systematically consider them.


Table 1. A comparison of the assumption regarding the caregiver consideration in the CEA

Indication	Name	HAS	ZiN	TLV	CADTH	ICER	PBAC
Dravet Syndrome	EPIDIOLEX®	●	●	●	-	-	●
Lennox-Gastaut Syndrome	EPIDIOLEX®	●	●	-	-	-	●
Batten disease	BRINEURA®	-	-	-	●	-	●
Malabsorption syndrome	REVESTIVE®	-	●	-	●	-	●
Spinal Muscular Atrophy	SPINRAZA®	●	●	●	●	Discussion	●
	ZOLGENSMA®	●	●	-	-		-
	EVRYSDI®	●	●	○	●		●

- Caregiver utility added in the base case - Similar assumption to NICE
- Caregiver utility added in the base case - Assumption not described
- Caregiver utility added in a scenario - Similar assumption to NICE
- Caregiver utility added in a scenario - Different assumption to NICE
- No caregiver part of the assessment
- No HTA assessment available

HTA AGENCIES' EXPECTATIONS FOR CAREGIVER HRQoL CONSIDERATION IN CEA FOR PEDIATRIC INDICATIONS

- If explicitly stated, HTA agencies will follow their position on the consideration – or not - of caregiver utility in CEA – base case or scenario.
- ZiN, TLV, CADTH, and PBAC opinions on caregiver assumption **lack transparency**, while NICE, HAS, and ICER are more detailed and assertive.
- There is **no clear consistency** among these assessments. The majority consider caregivers only in scenarios. However, regarding the methodological assumptions, there is a tendency to align with NICE.
- The figure below shows key data from 16 NICE and 14 other HTA appraisals:




DISCUSSION

- The HTA agencies selected in this research were chosen to best represent the diversity of opinions regarding caregiver HRQoL.
- Further studies on adult or elderly indications are needed to know whether HTA expectations identify for pediatric indications are similar.
- The assumption regarding the choice of method for implementing caregiver utility in the model has the heaviest impact on the results and raises the most ethical issues.
- In fact, for fatal diseases, the "disutility" method produces a counterintuitive effect - a **"Caregiver QALY trap"**².
- Consensus is needed** on which method – "utility", "disutility" or an alternative one - to use. Even though the "disutility" methods are always requested, NICE doesn't deny limitations.
- In addition, bereavement issues have been identified in some appraisals.

CONCLUSION

- This analysis led to draw 3 recommendations on the implementation of caregivers' HRQoL in a CEA for pediatric indications:



REFERENCES

- Pennington B, Eaton J, Hatswell AJ, Taylor H. Carers' Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations. Pharmacoeconomics. 2022 Sep;40(9):837-850. doi: 10.1007/s40273-022-01164-4. Epub 2022 Jul 12. PMID: 35821351; PMCID: PMC9363311.
- Mott DJ, Schirmacher H, Al-Janabi H, Guest S, Pennington B, Scheuer N, Shah KK, Skedgel C. Modelling Spillover Effects on Informal Carers: The Carer QALY Trap. Pharmacoeconomics. 2023 Dec;41(12):1557-1561. doi: 10.1007/s40273-023-01316-0. Epub 2023 Sep 2. PMID: 37659032; PMCID: PMC10635951.

DISCLOSURES

Lisa SUTOUR, Noémie ALLALI, Anne-Lise VATAIRE are Sanofi employees and may hold shares and/or stock options in the company.

CONTACT

Lisa SUTOUR: lisa.sutour@sanofi.com

This study was sponsored by Sanofi